Now Playing
|Videos|December 22, 2022
Impact of MDD Episode Duration and Recurrences
Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.
Advertisement
Advertisement
Trending on Patient Care Online
1
5 FDA Decisions for Primary Care to Know from September 2026
2
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
3
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
4
Long-Term and Real-World Safety Data on Antipsychotic Agitation Therapy
5